Blog
RSS FeedPosted by Michael Wonder on 07 Mar 2024
Pharmaceutical reform agreement review report
6 March 2024 - The Department of Health and Aged Care has conducted a review of Pharmaceutical Reform Agreements (PRAs), to ...
Posted by Michael Wonder on 15 Dec 2023
CSL Behring’s Hemgenix granted first ever direct access in France for haemophilia B gene therapy
13 December 2023 - CSL Behring has been granted Direct Access for Hemgenix (etranacogene dezaparvovec) by the French Ministry of ...
Posted by Michael Wonder on 05 Dec 2023
Government sends mixed message to global life science investors
5 December 2023 - The Government has published new terms for the Statutory Scheme for branded medicines, maintaining sales rebates ...
Posted by Michael Wonder on 12 Oct 2023
Life sciences leaders unite to condemn radical plans to rewrite medicines scheme
9 October 2023 - Over twenty industry leaders from companies supplying the NHS with essential medicines warn that radical plans to ...
Posted by Michael Wonder on 22 Sep 2023
PMPRB report shows increased plan costs, promising pharmaceutical innovation: expert
20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug ...
Posted by Michael Wonder on 24 Aug 2023
PMPRB report reveals most new medicines come to market with high treatment costs
22 August 2023 - The Patented Medicine Prices Review Board published today the 7th edition of its annual Meds Entry Watch ...
Posted by Michael Wonder on 20 Jul 2023
New Government consultation on medicine clawbacks will harm investment, says ABPI
19 July 2023 - In a move that will further damage UK life sciences investment, the Government has launched a ...
Posted by Michael Wonder on 14 May 2023
Negotiations begin for a new medicine pricing scheme
4 May 2023 - Negotiations for a new voluntary scheme for branded medicines pricing to open between the government, NHS ...
Posted by Michael Wonder on 01 May 2023
Canada’s health minister denies interfering in agency’s efforts to lower drug costs
27 April 2023 - Health Minister Jean-Yves Duclos says he has not exercised any undue political pressure on the independent ...
Posted by Michael Wonder on 13 Apr 2023
Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement
11 April 2023 - The aims of this study were to review the current interactions within and across regulatory and HTA ...
Posted by Michael Wonder on 05 Apr 2023
Are German drug pricing regulations chasing some drug makers away, causing them to withdraw products from the market?
5 April 2023 - Germany’s pharmaceutical market is the most important one on the European continent. ...
Posted by Michael Wonder on 20 Mar 2023
Resignations at Canada’s drug pricing panel raise independence questions
14 March 2023 - A member of Canada’s drug pricing regulator has resigned, stating the federal government has undermined the ...
Posted by Michael Wonder on 19 Mar 2023
Lower drug prices are a good thing. Canada’s approach to achieving them was not.
17 March 2023 - Over the past six years, the Patented Medicine Prices Review Board – Canada’s federal drug-price regulating agency ...
Posted by Michael Wonder on 03 Mar 2023
Health minister disputes claim he sided with big pharma, interfered with drug price consultations
1 March 2023 - Review board 'will never be subjected to political interference,' Duclos said. ...
Posted by Michael Wonder on 03 Mar 2023
ABPI response to Government Statutory Scheme rise
2 March 2023 - The Government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject ...